APAP + ICI: An emerging concern?
from OncoPharm Hosted by John Bossaer
Acetaminophen (or paracetamol) & immune checkpoint inhibitors are ubiquitous in oncology practices. So, when new translational research suggests APAP may decrease the effectiveness - well that seems like something worth talking about. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients: https://doi.org/10.1016/j.annonc.2022.05.010 Hepatotoxicity risk factors with ICIs: https://doi.org/10.1097/cji.0000000000000347
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 10 minutes long.
When was this OncoPharm episode published?
This episode was published on June 30, 2022.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.